Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified ba...

Full description

Bibliographic Details
Main Authors: Justin J. Wilkins, Brigitte Brockhaus, Haiqing Dai, Yulia Vugmeyster, Joleen T. White, Satjit Brar, Carlo L. Bello, Berend Neuteboom, Janet R. Wade, Pascal Girard, Akash Khandelwal
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12406

Internet

https://doi.org/10.1002/psp4.12406

Similar Items